Clinical Trial: Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT06836063) titled 'Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients' on Feb. 18.

Brief Summary: The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive Disorder (MDD).

Study Start Date: April 30

Study Type: INTERVENTIONAL

Condition: Major Depressive Disorder (MDD)

Intervention: DRUG: Ropanicant

Tablet dosage form, twice a day

DRUG: Placebo

Matching placebo tablets, twice a day

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Suven Life Sciences Limited

Disclaimer: Curated by HT Syndication....